Penn Dental Medicine


Alumni CDE » Update on Local Anesthetics and Analgesics

Date Tuesday, February 11, 2014
Time 6:30 – 9:00 p.m.
Credits 1.5 lecture credit hours
Tuition Free
Location Penn Club of New York, Spuce Room
30 W. 44th Street
New York, NY 10036
Register Register online

Course Description

This presentation will first review the biochemical and physiological mechanisms behind post-surgical dental pain and then discuss various double-blind randomized controlled trials on the efficacy of various analgesic agents following the surgical removal of impacted third molar teeth. The final portion of this discussion will focus on meta analysis data for various analgesics in both dental pain and other post-surgical pain models. An updated flexible analgesic schedule which was published in JADA in August 2013 will also be introduced.

Educational Objectives

Upon completion of this presentation, the participants will be able to:

  • Discuss the utility of the oral surgery pain model.
  • List various peripheral chemical mediators which contribute to post-surgical dental pain.
  • Compare the analgesic efficacy of NSAIDs to single entity oral opioids in randomized placebo controlled double-blind oral surgery pain studies.
  • Describe the rationale for combining opioid with non-opioid analgesic agents.
  • Compare the short-term side effect profile of NSAIDs versus opioids.
  • Discuss meta-analysis data on the numbers needed treat (NNT) to obtain one additional patient with at least 50% maximum pain relief beyond the placebo treatment.


Dr. Elliot Hersh: Dr. Hersh is a Professor of Pharmacology at the University of Pennsylvania School of Dental Medicine. He holds DMD, MS and PhD degrees from UMDNJ. He has won numerous teaching honors including the Basic Science Teaching Award 18 of the last 21 years and the Lindback Award for Distinguished Teaching, the highest teaching honor bestowed by the University. He has been an invited lecturer to numerous dental and medical organizations. He has more than 100 publications, abstracts and book chapters to his credit and conducts clinical trials in the areas of local anesthesia and pain control. He has been one of the principal investigators in the clinical development of such products as Advil® Liquigels, Lodine® -XL, Septocaine® with 1:200,000 epinephrine, Oraverse® the novel local anesthetic reversal agent, Zipsor® a rapid-release formulation of the NSAID diclofenac and most recently a post-marketing study intranasal ketorolac or SPRIX® in postsurgical dental implant pain patients. His current research projects include efficacy and safety studies of a novel intranasal local anesthetic solution containing tetracaine and oxymetazoline in an effort to provide pulpal anesthesia of maxillary teeth without the need for injections, and a study of CL-108, an opioid combination drug with an immediate release layer of the antiemetic promethazine in postsurgical wisdom tooth surgery pain. Dr. Hersh was the 2007 recipient of the IADR’s Distinguished Scientist Award in Pharmacology, Therapeutic and Toxicology.
The Robert Schattner Center
University of Pennsylvania
School of Dental Medicine
240 South 40th Street
Philadelphia, PA 19104-6030